Business Context and Reporting Period
Company: Core Scientific, Inc. (CORZ)
Filing Type: Form 8-K (Current Report)
Date of Report: July 7, 2025
Event: Entry into a Material Definitive Agreement (Merger Agreement) with CoreWeave, Inc.
On July 7, 2025, Core Scientific, Inc. entered into an Agreement and Plan of Merger with CoreWeave, Inc. ("Parent") and Miami Merger Sub I, Inc. ("Merger Sub"). Under the agreement, Merger Sub will merge with and into Core Scientific, with Core Scientific surviving as a wholly-owned subsidiary of CoreWeave.
Key Financial Metrics and Transaction Terms
Merger Consideration:
- Exchange Ratio: Each outstanding share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave Class A common stock.
- Stockholder Approval: The transaction requires the affirmative vote of holders of a majority of issued and outstanding shares of Core Scientific common stock.
Equity and Derivative Treatment:
- RSUs: Awards held by specified individuals (including Adam Sullivan, Jim Nygaard, and Todd DuChene) will fully vest and convert to CoreWeave stock. Other unvested RSUs will convert to "Parent Rollover RSU Awards" with substantially the same vesting terms.
- PSUs: Performance Stock Units held by specified individuals will vest at 300% performance level and convert. Others will convert to time-based awards assuming 300% performance.
- Options: "In the Money" options will be cancelled and converted to CoreWeave stock based on intrinsic value. "Out of the Money" options will be cancelled with no consideration.
- Warrants: Tranche 1 and Tranche 2 warrants will be converted into new warrants exercisable for CoreWeave Class A common stock, with adjusted exercise prices.
Termination Fee: If the Company's board changes its recommendation in favor of the Merger prior to stockholder approval, Core Scientific must pay CoreWeave a termination fee of $270 million.
Financial Data: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Core Scientific or CoreWeave. Investors should refer to the upcoming Form S-4 registration statement for detailed financial data.
Material Changes and Closing Conditions
The consummation of the Merger is subject to the satisfaction or waiver of the following conditions:
- Approval by Core Scientific stockholders.
- Effectiveness of the Form S-4 registration statement filed by CoreWeave.
- Expiration or termination of the HSR Act waiting period.
- Absence of any injunction or order prohibiting the Merger.
- Approval for listing of CoreWeave Class A common stock on the Nasdaq Global Select Market.
- No material adverse effect on either party since July 7, 2025.
Executive Compensation Changes:
- Excise Tax Gross-Ups: Named executive officers will receive gross-up payments if merger-related benefits are subject to the 1% excise tax under Section 4999 of the Internal Revenue Code. These agreements include a one-year non-compete covenant.
- Severance: Officers will separate from employment on the closing date (treated as "resignation for good reason"). Eligible officers will receive a lump sum cash severance equal to two times the sum of their annual base salary and target annual cash incentive bonus, plus 24 months of COBRA health coverage.
Guidance, Outlook, and Risks
Outlook: The parties have agreed to use reasonable best efforts to complete the Merger, including obtaining necessary regulatory approvals. The Company is restricted from soliciting alternative proposals, subject to customary exceptions for superior proposals.
Risks and Contingencies:
- Regulatory Approval: The transaction is subject to antitrust review and other governmental approvals.
- Stockholder Vote: Failure to obtain stockholder approval will result in termination.
- Integration Risks: Risks related to successfully integrating businesses and achieving anticipated synergies.
- Operational Disruption: Potential harm to business operations due to management distraction or transaction-related disruptions.
- Market Conditions: Risks related to the AI, power, data center, and crypto mining industries, including power availability and digital asset price volatility.
- Forward-Looking Statements: Actual results may differ materially from expectations due to various uncertainties.
Important Facts for Investor Verification
- Exchange Ratio: Verify the final exchange ratio of 0.1235 CoreWeave shares for each Core Scientific share.
- Termination Fee: Confirm the $270 million fee payable by Core Scientific if the board changes its recommendation.
- Executive Payouts: Review the specific severance and excise tax gross-up terms for named executives, which are contingent on the closing.
- Warrant Conversion: Verify the adjusted exercise prices and terms for converted Tranche 1 and Tranche 2 warrants.
- Regulatory Status: Monitor the status of the HSR waiting period and the effectiveness of the Form S-4 registration statement.
- Upcoming Documents: Await the definitive proxy statement/prospectus (Form S-4) for complete financial data and risk factors.